Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by The Wall Street Journal. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by The Wall Street Journal or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?

19:42
 
Share
 

Manage episode 484058775 series 2518362
Content provided by The Wall Street Journal. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by The Wall Street Journal or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

Blockbuster drugs. Rising profits. Strong sales. And yet, Novo Nordisk, the Danish company behind the GLP-1 drugs Ozempic and Wegovy, made a surprising move last week: It pushed out its CEO. WSJ's Peter Loftus charts the rise of Ozempic and the fall of CEO Lars Jorgensen. Jessica Mendoza hosts.

Further Listening:

Trillion Dollar Shot

Why WeightWatchers Wants in on Drugs Like Ozempic

Sign up for WSJ’s free What’s News newsletter.

Learn more about your ad choices. Visit megaphone.fm/adchoices

  continue reading

1506 episodes

Artwork
iconShare
 
Manage episode 484058775 series 2518362
Content provided by The Wall Street Journal. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by The Wall Street Journal or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

Blockbuster drugs. Rising profits. Strong sales. And yet, Novo Nordisk, the Danish company behind the GLP-1 drugs Ozempic and Wegovy, made a surprising move last week: It pushed out its CEO. WSJ's Peter Loftus charts the rise of Ozempic and the fall of CEO Lars Jorgensen. Jessica Mendoza hosts.

Further Listening:

Trillion Dollar Shot

Why WeightWatchers Wants in on Drugs Like Ozempic

Sign up for WSJ’s free What’s News newsletter.

Learn more about your ad choices. Visit megaphone.fm/adchoices

  continue reading

1506 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Listen to this show while you explore
Play